| Factor Information | |
|---|---|
| Data ID | 1004 |
| Factor | The second submodel Log(NT-proBNP) |
| Description | Results for the joint modeling analysis of a linear mixed effects model for NT-proBNP from before to 36 hours after surgery and a generalized linear model for the duration of inotropic therapy. |
| Biomarker | YES |
| Classification | Z (combined factor - combined factor) |
| Association | |
|---|---|
| Application | prognosis and risk assessment |
| Objective | To assess the relationship between N-terminal pro–brain natriuretic peptide (NT-proBNP) levels at different time points and early outcome, and to evaluate the reliability of NT-proBNP level as a predictor of early outcome after surgery in a large series of children with congenital heart disease (CHD). |
| p Value | 0.01 |
| Conclusion | Having adjusted for confounding variables, there was still a 3.5% (multivariate P = 0.01) increase in the likelihood of prolonged duration of inotropic therapy for each 1% increase in NT-proBNP. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 495 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/ASD/TAPVR/TOF/TGA/PA/ASD/CoA/DORV/IAA/PS/other |
| Reference | |
|---|---|
| PMID | 28283228 |
| Year | 2017 |
| Title | Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery. |
| Sample | ||
|---|---|---|
| Population | children | |
| Source | Blood | |
| Region | Guangzhou,China | |
| Method | A retrospective observational study involving 363 consecutive children with CHD was used. Plasma NT-proBNP records were obtained for each patient before and 1, 12, and 36 hours after surgery. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | cardiac surgery | |
| Group | total CHD(Treatment) | total CHD(Control) |
| Number | 363 | 363 |
| Age | 15.8 ± 27.4 months | 15.8 ± 27.4 months |
| Gender (Male: Female) | 235:128 (total) | 235:128 (total) |
| Marker Level | Estimate(95% CI)=0.03 (0.01 to 0.06) RE%: 3.46 | Estimate: N/A |
